Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
93% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VNDA' s Cash to Debt Range Over the Past 10 Years
Min: 44.31  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.62
VNDA's Equity to Asset is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VNDA: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
VNDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: 0.94
Current: 0.62
0.07
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
90% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 3.82
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -12.72
VNDA's Operating margin (%) is ranked higher than
65% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. VNDA: -12.72 )
Ranked among companies with meaningful Operating margin (%) only.
VNDA' s Operating margin (%) Range Over the Past 10 Years
Min: -790.41  Med: -35.4 Max: 40
Current: -12.72
-790.41
40
Net-margin (%) -12.33
VNDA's Net-margin (%) is ranked higher than
65% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. VNDA: -12.33 )
Ranked among companies with meaningful Net-margin (%) only.
VNDA' s Net-margin (%) Range Over the Past 10 Years
Min: -788.46  Med: -33.81 Max: 40.25
Current: -12.33
-788.46
40.25
ROE (%) -14.11
VNDA's ROE (%) is ranked higher than
65% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. VNDA: -14.11 )
Ranked among companies with meaningful ROE (%) only.
VNDA' s ROE (%) Range Over the Past 10 Years
Min: -134.08  Med: -52.74 Max: 23.67
Current: -14.11
-134.08
23.67
ROA (%) -8.65
VNDA's ROA (%) is ranked higher than
69% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. VNDA: -8.65 )
Ranked among companies with meaningful ROA (%) only.
VNDA' s ROA (%) Range Over the Past 10 Years
Min: -111.28  Med: -16.55 Max: 12.81
Current: -8.65
-111.28
12.81
ROC (Joel Greenblatt) (%) -405.25
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. VNDA: -405.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VNDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4620.09  Med: -1029.58 Max: 784.55
Current: -405.25
-4620.09
784.55
Revenue Growth (3Y)(%) 44.40
VNDA's Revenue Growth (3Y)(%) is ranked higher than
88% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. VNDA: 44.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VNDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -1.85 Max: 90.4
Current: 44.4
0
90.4
EBITDA Growth (3Y)(%) -37.60
VNDA's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. VNDA: -37.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VNDA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.3 Max: 22.5
Current: -37.6
0
22.5
EPS Growth (3Y)(%) -15.90
VNDA's EPS Growth (3Y)(%) is ranked lower than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. VNDA: -15.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VNDA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -30.5 Max: -2.4
Current: -15.9
GuruFocus has detected 2 Warning Signs with Vanda Pharmaceuticals Inc $VNDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VNDA Guru Trades in Q1 2016

Jim Simons 416,900 sh (+23.57%)
Paul Tudor Jones Sold Out
John Paulson 3,927,000 sh (-0.49%)
» More
Q2 2016

VNDA Guru Trades in Q2 2016

Paul Tudor Jones 12,719 sh (New)
Joel Greenblatt 14,304 sh (New)
John Paulson 3,864,717 sh (-1.59%)
Jim Simons 151,050 sh (-63.77%)
» More
Q3 2016

VNDA Guru Trades in Q3 2016

Steven Cohen 542,700 sh (New)
Paul Tudor Jones 48,953 sh (+284.88%)
Jim Simons 432,050 sh (+186.03%)
Joel Greenblatt 27,244 sh (+90.46%)
John Paulson 2,175,000 sh (-43.72%)
» More
Q4 2016

VNDA Guru Trades in Q4 2016

Joel Greenblatt 60,217 sh (+121.03%)
Jim Simons 568,350 sh (+31.55%)
Paul Tudor Jones 50,547 sh (+3.26%)
John Paulson Sold Out
Steven Cohen 151,100 sh (-72.16%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:SXMDF, NAS:NDRM, NYSE:MYOV, OTCPK:GNFTF, OTCPK:PHMMF, NAS:ARDX, NAS:ACIU, OTCPK:IPHYF, NAS:WVE, NAS:ASND, NAS:CRSP, NAS:RVNC, NAS:ACRS, NAS:ACHN, NAS:ANIK, NAS:EPZM, NAS:PGNX, NAS:ITCI, NAS:MGNX, NAS:VSAR » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.

Vanda Pharmaceuticals Inc was incorporated in Delaware on November 13, 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. Its product portfolio includes HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt (iloperidone) a product for the treatment of schizophrenia, the oral formulation; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities. The Company faces competition from competitors including Sunovion Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceuticals Company Limited, Pernix Therapeutics, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd, Neurim Pharmaceuticals, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Alkermes, Inc and Actavis PLC. The Company's business is subject to extensive government regulation and oversight.

Ratios

vs
industry
vs
history
P/B 4.85
VNDA's P/B is ranked lower than
64% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. VNDA: 4.85 )
Ranked among companies with meaningful P/B only.
VNDA' s P/B Range Over the Past 10 Years
Min: 2.53  Med: 5.68 Max: 623.46
Current: 4.85
2.53
623.46
P/S 4.29
VNDA's P/S is ranked higher than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. VNDA: 4.29 )
Ranked among companies with meaningful P/S only.
VNDA' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 5.89 Max: 69.88
Current: 4.29
2.63
69.88
EV-to-EBIT -26.72
VNDA's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. VNDA: -26.72 )
Ranked among companies with meaningful EV-to-EBIT only.
VNDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1288.6  Med: -0.75 Max: 578.2
Current: -26.72
-1288.6
578.2
EV-to-EBITDA -73.97
VNDA's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. VNDA: -73.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
VNDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -83.3  Med: -0.15 Max: 81.6
Current: -73.97
-83.3
81.6
Current Ratio 3.46
VNDA's Current Ratio is ranked lower than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. VNDA: 3.46 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 3.25  Med: 6.46 Max: 18.2
Current: 3.46
3.25
18.2
Quick Ratio 3.45
VNDA's Quick Ratio is ranked lower than
55% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. VNDA: 3.45 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 3.22  Med: 6.46 Max: 17.54
Current: 3.45
3.22
17.54
Days Inventory 14.19
VNDA's Days Inventory is ranked higher than
89% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. VNDA: 14.19 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 14.19  Med: 151.44 Max: 596.04
Current: 14.19
14.19
596.04
Days Sales Outstanding 50.66
VNDA's Days Sales Outstanding is ranked higher than
60% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. VNDA: 50.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 24.24 Max: 253.93
Current: 50.66
5.22
253.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.60
VNDA's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. VNDA: -9.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VNDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -6.35 Max: 0
Current: -9.6
-14.9
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.21
VNDA's Price/Net Cash is ranked lower than
71% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. VNDA: 10.21 )
Ranked among companies with meaningful Price/Net Cash only.
VNDA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.31  Med: 11.23 Max: 125
Current: 10.21
0.31
125
Price/Net Current Asset Value 6.71
VNDA's Price/Net Current Asset Value is ranked lower than
60% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. VNDA: 6.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VNDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.3  Med: 10.51 Max: 185
Current: 6.71
0.3
185
Price/Tangible Book 6.14
VNDA's Price/Tangible Book is ranked lower than
66% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. VNDA: 6.14 )
Ranked among companies with meaningful Price/Tangible Book only.
VNDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 6.77 Max: 31.09
Current: 6.14
0.29
31.09
Price/Median PS Value 0.73
VNDA's Price/Median PS Value is ranked higher than
68% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. VNDA: 0.73 )
Ranked among companies with meaningful Price/Median PS Value only.
VNDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.04 Max: 11.36
Current: 0.73
0.54
11.36
Earnings Yield (Greenblatt) (%) -3.77
VNDA's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. VNDA: -3.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VNDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.78  Med: 34.4 Max: 3521.3
Current: -3.77
-3.78
3521.3

More Statistics

Revenue (TTM) (Mil) $146.0
EPS (TTM) $ -0.42
Beta0.97
Short Percentage of Float5.84%
52-Week Range $6.95 - 18.00
Shares Outstanding (Mil)43.95

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) 2.29
EPS w/o NRI ($) 2.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Feb 21 2017
VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Feb 17 2017
Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT Feb 15 2017
Vanda reports 4Q loss Feb 15 2017
Vanda reports 4Q loss Feb 15 2017
Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Feb 15 2017
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 15 2017
Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results Feb 15 2017
Q4 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close Feb 15 2017
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February... Jan 19 2017
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017... Jan 09 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016
Prima (PBMD) Reports Favorable Initial Melanoma Study Data Dec 30 2016
Shire Gets FDA Approval for Label Expansion of Adynovate Dec 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)